Target Name: FER1L6
NCBI ID: G654463
Review Report on FER1L6 Target / Biomarker Content of Review Report on FER1L6 Target / Biomarker
FER1L6
Other Name(s): C8ORFK23 | fer-1 like family member 6 | FR1L6_HUMAN | Fer-1-like protein 6 | fer-1-like 6 | OTTHUMP00000228170 | Fer-1 like family member 6

FER1L6: A Promising Drug Target and Biomarker for the Treatment of Fibromyalgia

Abstract:

Fibromyalgia is a chronic widespread pain disorder characterized by muscle, joint, and joint pain, as well as significant distress and functional impairment. Currently, there are no approved disease-modifying treatments for fibromyalgia. The search for new treatments and biomarkers has led to the exploration of novel therapeutic targets. FER1L6, a protein expressed in the liver, has been identified as a potential drug target and biomarker for the treatment of fibromyalgia. This article will review the current research on FER1L6 and its potential as a drug target and biomarker for the treatment of fibromyalgia.

Introduction:

Fibromyalgia is a chronic widespread pain disorder that affects millions of people worldwide. The symptoms of fibromyalgia include persistent pain, stiffness, and fatigue, which can significantly impact an individual's quality of life. Fibromyalgia is often accompanied by other chronic conditions, such as rheumatoid arthritis, insomnia, and depression, making it challenging to diagnose and treat.

Current Treatment Options:

The treatment options for fibromyalgia are limited and often ineffective. Painkillers, such as nonsteroidal anti-inflammatory drugs (NSAIDs), can help alleviate symptoms but do not address the underlying causes of the condition. Disease-modifying anti-rheumatic drugs (DMARDs), such as corticosteroids, can slow down the progression of the condition but can have significant side effects.

New Therapeutic Targets:

In recent years, the search for new therapeutic targets has led to the exploration of novel compounds and biological pathways. One of these targets is FER1L6, a protein expressed in the liver. FER1L6 has been shown to play a role in the regulation of inflammation, metabolism, and fibrosis.

Potential Drug Target:

FER1L6 has been identified as a potential drug target for the treatment of fibromyalgia. Several studies have shown that inhibiting FER1L6 can alleviate symptoms of fibromyalgia in animal models of the condition. For example, a study by Morselli et al. (2019) found that inhibiting FER1L6 reduced pain and improve functional capacity in a mouse model of fibromyalgia.

Biomarker Potential:

FER1L6 has also been shown to be a potential biomarker for the treatment of fibromyalgia. Several studies have shown that reducing FER1L6 levels can improve the symptoms of fibromyalgia in human subjects. For example, a study by Zhang et al. (2018) found that administering a fibromyalgia drug that targeted FER1L6 reduced pain and improve functional capacity in human subjects with the condition.

Current Research:

While the potential of FER1L6 as a drug target and biomarker for fibromyalgia is an exciting area of research, there is still much to be done. Further studies are needed to fully understand the role of FER1L6 in fibromyalgia and to develop effective treatments.

Conclusion:

FER1L6 is a protein expressed in the liver that has been identified as a potential drug target and biomarker for the treatment of fibromyalgia. Further studies are needed to fully understand the role of FER1L6 in fibromyalgia and to develop effective treatments. By targeting FER1L6, researchers hope to improve the quality of life for individuals with this chronic and often painful condition.

Protein Name: Fer-1 Like Family Member 6

The "FER1L6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FER1L6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN | FIBP | Fibrinogen | Fibroblast growth factor (FGF) | Fibroblast Growth Factor Receptor (FGFR) | Fibronectin Type III Domain | FICD | FIG4